Background As the COVID-19 pandemic continues to spread, the number of associated
deaths continues to increase, especially among those with pre-existing conditions. Azvudine …

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

Objective To estimate the effectiveness of nirmatrelvir, compared with no treatment, in
reducing admission to hospital or death at 30 days in people infected with the SARS-CoV-2 …

Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …

Description: The American College of Physicians and American Academy of Family
Physicians developed this guideline to present the available evidence on current …

Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to
prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r …

To date, there is a lack of randomized trial data examining the use of the antiviral
nirmatrelvir/ritonavir in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …